Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Chinese Journal of Hematology ; (12): 490-494, 2023.
Artículo en Chino | WPRIM | ID: wpr-984649

RESUMEN

Objective: To investigate the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKi) ibrutinib or zanubrutinib monotherapy in newly diagnosed patients with Waldenström macroglobulinemia (WM) . Methods: The efficacy and adverse effects of 58 patients with newly diagnosed WM receiving BTKi monotherapy in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were analyzed retrospectively from January 2018 to August 2022. Results: The response of 55 patients may be examined. Forty patients received ibrutinib monotherapy for a median of 15 months, with an overall response rate (ORR) of 85%, a main remission rate (MRR) of 70%, and a very good partial remission (VGPR) rate of 10%. Fifteen patients received zanubrutinib monotherapy for a median of 13 months, with an ORR of 93%, an MRR of 73%, and a VGPR rate of 0%. For various reasons, 10 patients were converted from ibrutinib to zanubrutinib. Ibrutinib treatment lasted an average of 7.5 months before conversion. The median duration of zanubrutinib therapy after conversion was 3.5 months. The ORRs before and after conversion were 90% and 100%, MRRs were 80% and 80%, and VGPR rates were 10% and 50%, respectively. After a median of 16 months, the 24-month progression-free survival (PFS) rate of patients who received both BTKi was 86%. PFS did not differ statistically across individuals with low, medium, and high-risk ISS scores (P=0.998). All of the patients survived. The most common side effects of BTKi were neutropenia and thrombocytopenia, which occurred in 12% and 10% of all patients, respectively. Ibrutinib accounts for 5% of atrial fibrillation, and zanubrutinib has a 7% risk of bleeding. Conclusions: In treating WM, ibrutinib or zanubrutinib provides good efficacy and tolerable adverse effects.


Asunto(s)
Humanos , China , Estudios Retrospectivos , Resultado del Tratamiento , Inhibidor de la Tirosina Quinasa/uso terapéutico , Macroglobulinemia de Waldenström/tratamiento farmacológico
2.
Rev. méd. Chile ; 147(3): 275-280, mar. 2019. tab, graf
Artículo en Español | LILACS | ID: biblio-1004347

RESUMEN

Background: Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein. Aim: To evaluate the clinical characteristics, management and results of treatment of patients with WM at a public hospital in Chile. Patients and Methods: Review of medical records of 31 patients aged 43 to 85 years (16 males) with WM diagnosed between 2002 and 2017. Clinical features and survival were recorded. Results: All patients had bone marrow compromise, and 31%, extranodal involvement. According to the International Prognostic Score System for WM (IPSSWM) 16, 58 and 26% were at low, intermediate and high risk, respectively. Twenty-five patients (81%) were treated, 32% with plasmapheresis and 36% with rituximab. Four cases (16%) achieved complete remission. Median follow up was 35 months (range 6-159). Estimated overall survival (OS) at 5 and 10 years was 74% and 53%, respectively. According to IPSSWM, the estimated five-year OS was 80, 92 and 39%, for low, intermediate and high-risk patients, respectively. Conclusions: OS was similar to that reported abroad, except for low risk patients, probably due to the low number of cases and short follow up. An improved survival should be expected with the routine use of immunochemotherapy.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Macroglobulinemia de Waldenström/diagnóstico , Vincristina , Biopsia , Médula Ósea/patología , Prednisona/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Chile/epidemiología , Tasa de Supervivencia , Estudios Retrospectivos , Resultado del Tratamiento , Macroglobulinemia de Waldenström/mortalidad , Macroglobulinemia de Waldenström/tratamiento farmacológico , Ciclofosfamida/uso terapéutico , Rituximab/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico
3.
Rev. Soc. Bras. Clín. Méd ; 16(3): 176-179, jul.-set. 2018. tab., ilus.
Artículo en Portugués | LILACS | ID: biblio-1047953

RESUMEN

A miocardiopatia não compactada é uma doença congênita rara, que pode ocorrer isoladamente ou associada a outros defeitos, por falha no processo de compactação das fibras miocárdicas, resultando na persistência de trabeculações e recessos profundos. A associação entre a miocardiopatia não compactada e gestação é incomum na literatura, assim como a relação com macroglobulinemia de Waldenstrom, um tipo de linfoma não Hodgkin. Descrevemos aqui a rara associação destas três patologias. Trata-se de paciente do sexo feminino, sem antecedentes hematológicos, neoplasias ou cardiopatias, que procurou o serviço com queixa de astenia progressiva, dores no corpo, perda ponderal importante e anemia. Na investigação diagnóstica, a imunoeletroforese de proteína constatou pico monoclonal em IgM Kappa, com inventário medular por imunofenotipagem e biópsia de medula óssea com Kappa+, CD19+, CD20+, CD38 e CD79b, confirmando diagnóstico de neoplasia de linfócitos B maduros. Na terapêutica, optou-se pelo esquema de primeira linha com dexametasona, rituximabe e ciclofosfamida (DRC) − este último considerado agente alquilante cardiotóxico. Em triagem pré-quimioterápica, o eletrocardiograma mostrou alteração da repolarização ventricular anterosseptal. O ecocardiograma transtorácico evidenciou trabeculações excessivas no ápice do ventrículo esquerdo, sugerindo não compactação do miocárdio. A ressonância magnética confirmou o diagnóstico. Foi iniciada terapia com metoprolol e ácido acetilsalisílico. Todavia, após o último ciclo de terapia quimioterápica, paciente descobriu gravidez (G1P1A0). O período gestacional e o puerpério evoluíram sem manifestações clínicas de insuficiência cardíaca, em classe funcional I (New York Heart Association), mesmo com redução da fração de ejeção do ventrículo esquerdo ao ecocardiograma transtorácico. (AU)


Non-compaction cardiomyopathy is a rare congenital disease that can occur in isolation or associated with other defects, due to failure in compaction of myocardial fiber, resulting in persistence of myocardial trabeculations and deep recesses. The association between non-compaction cardiomyopathy and gestation, as well as the relationship with Waldenstrom's macrobulinemia, a type of Non-Hodgkin's Lymphoma (NHL), are not common in the literature. This study describes the rare association of these three pathologies. This is the case of a female patient with no history of hematological, neoplastic, or heart diseases, who sought the service with complaints of progressive weakness, body aches, important weight loss, and anemia. During the diagnostic investigation, protein immunoelectrophoresis showed a monoclonal peak in IgM Kappa monoclonal gammopathy, with a medullary inventory by immunophenotyping and bone marrow biopsy with Kappa+, CD19+, CD20+, CD38 and CD79b, confirming the diagnosis of mature B-cell lymphocyte neoplasm. The first line therapy chosen was dexamethasone, rituximab, and cyclophosphamide (CKD), with the latter being considered a cardiotoxic alkylating agent. At pre-chemotherapy screening, the electrocardiogram showed an alteration of the anteroseptal ventricular repolarization. Transthoracic echocardiography (ETT) showed excessive trabeculations at the apex of the left ventricle (LV), suggesting no compaction of the myocardium. The magnetic resonance imaging confirmed the diagnosis.Therapy with metoprolol and acetylsalicylic acid was started. However, after the last cycle of chemotherapy, the patient found she was pregnant (G1P1A0). The gestational and puerperium period progressed with no clinical manifestations of heart failure, in functional class I (New York Heart Association), albeit the reduction of the ejection fraction of the left ventricular shown in the transthoracic echocardiography. (AU)


Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Complicaciones Cardiovasculares del Embarazo/diagnóstico por imagen , Complicaciones Neoplásicas del Embarazo/diagnóstico , Macroglobulinemia de Waldenström/diagnóstico , Cardiomiopatías/diagnóstico por imagen , Trombocitopenia/tratamiento farmacológico , Biopsia con Aguja , Dexametasona/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Ecocardiografía , Espectroscopía de Resonancia Magnética , Macroglobulinemia de Waldenström/tratamiento farmacológico , Antagonistas Adrenérgicos beta/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Antineoplásicos Alquilantes/uso terapéutico , Ciclofosfamida/uso terapéutico , Electrocardiografía , Rituximab/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico
5.
Bol. Hosp. San Juan de Dios ; 45(1): 43-8, feb. 1998. tab
Artículo en Español | LILACS | ID: lil-210518

RESUMEN

Se presenta el caso clínico de un hombre de 70 años que consultó luego de varios meses de mareos, cansancio muscular, baja de peso y palidez. El estudio realizado demostró: pancitopenia con anemia normocítica, normocrómica, arregenerativa; hiperproteínemia con un componente monoclonal; gammapatía monoclonal IgM kappa con cadena liviana lambda libre; ausencia de lesiones osteolíticas; médula ósea con infiltración linfomatosa y disminución de las series eritroide, mieloide y megacariocítica pero sólo con 3 por ciento de plasmocitos; hiperviscosidad sanguínea. Luego de dos ciclos de melfalan y prednisona el paciente reingresa con un síndrome febril y compromiso de conciencia y fallece a los pocas horas con una sepsis a gram negativos (Escherichia coli) y una infección meníngea


Asunto(s)
Humanos , Masculino , Anciano , Macroglobulinemia de Waldenström/diagnóstico , Escherichia coli/patogenicidad , Resultado Fatal , Macroglobulinemia de Waldenström/complicaciones , Macroglobulinemia de Waldenström/tratamiento farmacológico , Melfalán/uso terapéutico , Pancitopenia/tratamiento farmacológico , Pancitopenia/etiología , Paraproteinemias/clasificación , Prednisolona/uso terapéutico , Sepsis/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA